Dimenäs E, Kerr D, Macdonald I
Research Laboratories, AB Hässle, Mölndal, Sweden.
J Clin Pharmacol. 1990 Feb;30(S2):S103-7. doi: 10.1002/j.1552-4604.1990.tb03506.x.
The effect of once daily treatment with atenolol (100 mg), metoprolol CR/ZOK (100 mg) and propranolol LA (160 mg) for one week on CNS-related subjective symptoms was compared with that of placebo using a randomised, double-blind cross-over design in 12 healthy volunteers. The symptoms were recorded using a previously documented self-administered questionnaire (MSE-profile), which included three dimensions: Contentment, Vitality and Sleep. Compared to placebo, all three beta-adrenoceptor antagonists reduced the exercise heart rate at 24 hours but a somewhat more pronounced effect was found with propranolol LA. No significant difference in any of the dimensions was detected between placebo and either metoprolol CR/ZOK or atenolol tablets. Following propranolol LA treatment a deterioration in the dimensions Vitality and Sleep was observed compared with both placebo and the beta 1-selective drugs. Difference in lipophilicity between the beta 1-selective agents metoprolol and atenolol has little bearing on the occurrence of the CNS-related symptoms, in comparison to the marked effects of the lipophilic and nonselective compound propranolol.
在12名健康志愿者中,采用随机、双盲交叉设计,比较了阿替洛尔(100毫克)、美托洛尔控释片/琥珀酸盐(100毫克)和普萘洛尔长效制剂(160毫克)每日一次治疗一周对中枢神经系统相关主观症状的影响与安慰剂的效果。使用先前记录的自我管理问卷(MSE-profile)记录症状,该问卷包括三个维度:满意度、活力和睡眠。与安慰剂相比,所有三种β-肾上腺素能受体拮抗剂均降低了24小时运动心率,但普萘洛尔长效制剂的效果更为明显。在安慰剂与美托洛尔控释片/琥珀酸盐或阿替洛尔片之间,未检测到任何维度上的显著差异。与安慰剂和β1选择性药物相比,普萘洛尔长效制剂治疗后,活力和睡眠维度出现恶化。与亲脂性和非选择性化合物普萘洛尔的显著影响相比,β1选择性药物美托洛尔和阿替洛尔之间的亲脂性差异对中枢神经系统相关症状的发生影响不大。